Nerve growth factor administration protects against experimental diabetic sensory neuropathy

Stuart C. Apfel, Joseph C. Arezzo, Michael Brownlee, Howard Federoff, John A. Kessler

Research output: Contribution to journalArticle

274 Citations (Scopus)

Abstract

Small fiber sensory neuropathy is one of the most common complications of diabetes mellitus. Currently there is no adequate therapy to prevent this often debilitating problem. Nerve growth factor (NGF) is a protein that promotes the survival and integrity of a large percentage of sensory neurons including the small fiber pain transmitting neurons which are often prominently affected in diabetic neuropathy. We report here that exogenously administered NGF is capable of preventing the behavioral and biochemical manifestations of diabetic sensory neuropathy in a streptozocin induced rat model. NGF administration prevented the elevation of tailflick threshold (a measure of the rat's response to a thermal noxious stimulus) which occured in streptozocin-induced diabetic rats. Further, it prevented the induced reduction in levels of the neurpeptides substance P and calcitonin gene related peptide measured from cervical dorsal root ganglia. Finally, NGF did not ameliorate the prolonged latency of the compound action potentials measured from the caudal nerve of the tail. In view of these results, a clinical trial of NGF in diabetic neuropathy has now commenced.

Original languageEnglish (US)
Pages (from-to)7-12
Number of pages6
JournalBrain Research
Volume634
Issue number1
DOIs
StatePublished - Jan 14 1994

Fingerprint

Diabetic Neuropathies
Nerve Growth Factor
Streptozocin
Calcitonin Gene-Related Peptide
Spinal Ganglia
Sensory Receptor Cells
Diabetes Complications
Substance P
Action Potentials
Tail
Hot Temperature
Clinical Trials
Neurons
Pain
Proteins

Keywords

  • Neuropathy
  • NGF
  • Rat
  • Treatment

ASJC Scopus subject areas

  • Developmental Biology
  • Molecular Biology
  • Clinical Neurology
  • Neuroscience(all)

Cite this

Nerve growth factor administration protects against experimental diabetic sensory neuropathy. / Apfel, Stuart C.; Arezzo, Joseph C.; Brownlee, Michael; Federoff, Howard; Kessler, John A.

In: Brain Research, Vol. 634, No. 1, 14.01.1994, p. 7-12.

Research output: Contribution to journalArticle

Apfel, Stuart C. ; Arezzo, Joseph C. ; Brownlee, Michael ; Federoff, Howard ; Kessler, John A. / Nerve growth factor administration protects against experimental diabetic sensory neuropathy. In: Brain Research. 1994 ; Vol. 634, No. 1. pp. 7-12.
@article{c8146c9fc3174b01819f32964411de38,
title = "Nerve growth factor administration protects against experimental diabetic sensory neuropathy",
abstract = "Small fiber sensory neuropathy is one of the most common complications of diabetes mellitus. Currently there is no adequate therapy to prevent this often debilitating problem. Nerve growth factor (NGF) is a protein that promotes the survival and integrity of a large percentage of sensory neurons including the small fiber pain transmitting neurons which are often prominently affected in diabetic neuropathy. We report here that exogenously administered NGF is capable of preventing the behavioral and biochemical manifestations of diabetic sensory neuropathy in a streptozocin induced rat model. NGF administration prevented the elevation of tailflick threshold (a measure of the rat's response to a thermal noxious stimulus) which occured in streptozocin-induced diabetic rats. Further, it prevented the induced reduction in levels of the neurpeptides substance P and calcitonin gene related peptide measured from cervical dorsal root ganglia. Finally, NGF did not ameliorate the prolonged latency of the compound action potentials measured from the caudal nerve of the tail. In view of these results, a clinical trial of NGF in diabetic neuropathy has now commenced.",
keywords = "Neuropathy, NGF, Rat, Treatment",
author = "Apfel, {Stuart C.} and Arezzo, {Joseph C.} and Michael Brownlee and Howard Federoff and Kessler, {John A.}",
year = "1994",
month = "1",
day = "14",
doi = "10.1016/0006-8993(94)90252-6",
language = "English (US)",
volume = "634",
pages = "7--12",
journal = "Brain Research",
issn = "0006-8993",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Nerve growth factor administration protects against experimental diabetic sensory neuropathy

AU - Apfel, Stuart C.

AU - Arezzo, Joseph C.

AU - Brownlee, Michael

AU - Federoff, Howard

AU - Kessler, John A.

PY - 1994/1/14

Y1 - 1994/1/14

N2 - Small fiber sensory neuropathy is one of the most common complications of diabetes mellitus. Currently there is no adequate therapy to prevent this often debilitating problem. Nerve growth factor (NGF) is a protein that promotes the survival and integrity of a large percentage of sensory neurons including the small fiber pain transmitting neurons which are often prominently affected in diabetic neuropathy. We report here that exogenously administered NGF is capable of preventing the behavioral and biochemical manifestations of diabetic sensory neuropathy in a streptozocin induced rat model. NGF administration prevented the elevation of tailflick threshold (a measure of the rat's response to a thermal noxious stimulus) which occured in streptozocin-induced diabetic rats. Further, it prevented the induced reduction in levels of the neurpeptides substance P and calcitonin gene related peptide measured from cervical dorsal root ganglia. Finally, NGF did not ameliorate the prolonged latency of the compound action potentials measured from the caudal nerve of the tail. In view of these results, a clinical trial of NGF in diabetic neuropathy has now commenced.

AB - Small fiber sensory neuropathy is one of the most common complications of diabetes mellitus. Currently there is no adequate therapy to prevent this often debilitating problem. Nerve growth factor (NGF) is a protein that promotes the survival and integrity of a large percentage of sensory neurons including the small fiber pain transmitting neurons which are often prominently affected in diabetic neuropathy. We report here that exogenously administered NGF is capable of preventing the behavioral and biochemical manifestations of diabetic sensory neuropathy in a streptozocin induced rat model. NGF administration prevented the elevation of tailflick threshold (a measure of the rat's response to a thermal noxious stimulus) which occured in streptozocin-induced diabetic rats. Further, it prevented the induced reduction in levels of the neurpeptides substance P and calcitonin gene related peptide measured from cervical dorsal root ganglia. Finally, NGF did not ameliorate the prolonged latency of the compound action potentials measured from the caudal nerve of the tail. In view of these results, a clinical trial of NGF in diabetic neuropathy has now commenced.

KW - Neuropathy

KW - NGF

KW - Rat

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=0027976369&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027976369&partnerID=8YFLogxK

U2 - 10.1016/0006-8993(94)90252-6

DO - 10.1016/0006-8993(94)90252-6

M3 - Article

VL - 634

SP - 7

EP - 12

JO - Brain Research

JF - Brain Research

SN - 0006-8993

IS - 1

ER -